Rosiglitazone and Risk of Cancer
Open accessAbstract
OBJECTIVE: Despite experimental data suggesting a protective effect of peroxisome proliferator-activated receptor-gamma agonists with respect to malignancies, results of available epidemiological studies on the incidence of cancer in rosiglitazone-treated patients are not univocal. The aim of this meta-analysis of randomized clinical trials is to assess the effect of rosiglitazone on the incidence of cancer. RESEARCH DESIGN AND METHODS: Randomized clinical trials of rosiglitazone with duration of >24 weeks were retrieved through Medline and from the GlaxoSmithKline Web site, which reports main results of all trials sponsored by GlaxoSmithKline; incident malignancies were retrieved from the summary of serious adverse events. Proportions of outcome measures across treatment groups were compared by odds ratios (ORs) and 95% CI. Considering differences in the duration of follow-up among treatment arms in some of the trials, we also calculated the incidence of cancer in rosiglitazone and control groups. RESULTS: Eighty trials, enrolling 16,332 and 12,522 patients in the rosiglitazone and comparator groups, respectively, were retrieved. Rosiglitazone was not associated with a significant modification of the risk of cancer (OR 0.91 [95% CI 0.71-1.16], P = 0.44). The incidence of malignancies was significantly lower in rosiglitazone-treated patients than in control groups (0.23 [0.19-0.26] vs. 0.44 [0.34-0.58] cases/100 patient-years; P < 0.05). CONCLUSIONS: The use of rosiglitazone appears to be safe in terms of incidence of cancer, whereas its possible protective effect needs to be further investigated.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A recent meta-analysis of clinical trials of rosiglitazone showed no statistically significant increase or decrease in the risk of cancer at all sites combined or at the more common sites, although the numbers of cancer cases at these specific sites were small.
“Results of a recent meta-analysis of clinical trials of rosiglitazone showed no statistically significant increase or decrease in the risk of cancer at all sites combined or at the more common sites, although the numbers of cancer cases at these specific sites were small (107).”
From Diabetes and Cancer (2010) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · see citing works
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · see citing works
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · see citing works
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830 · see citing works
Demetri, G. D., Fletcher, C. D. �., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3951 · Cited by 495 · see citing works
Mueller, E., Smith, M. R., Sarraf, P., Kroll, T. G., Aiyer, A., Kaufman, D. S., Oh, W. K., Demetri, G. D., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 427 · see citing works
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336 · see citing works
Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
Diamond, G. A., Bax, L., & Kaul, S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00182 · Cited by 288 · see citing works
Rosiglitazone and Cardiovascular Risk
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 179 · see citing works
Han, S., & Roman, J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0347 · Cited by 171 · see citing works
A phase II trial with rosiglitazone in liposarcoma patients
Debrock, G., Vanhentenrijk, V., Sciot, R., Dêbiec‐Rychter, M., Oyen, R., & van Oosterom, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601306 · Cited by 161 · see citing works
Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R. A., Clark, J. S., Spiegelman, B. M., Kim, H. T., Mayer, R. J., & Fuchs, C. S. (2002) · The Cancer Journal · doi:10.1097/00130404-200209000-00010 · Cited by 150 · see citing works
Polycystic Ovary Syndrome and Endometrial Cancer
Navaratnarajah, R., Pillay, O., & Hardiman, P. J. (2008) · Seminars in Reproductive Medicine · doi:10.1055/s-2007-992926 · Cited by 136 · see citing works
Shuster, J. J., Jones, L. S., & Salmon, D. A. (2007) · Statistics in Medicine · doi:10.1002/sim.3060 · Cited by 105 · see citing works
Ramos-Nino, M. E., MacLean, C. D., & Littenberg, B. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-17 · Cited by 92 · see citing works
Galli, A., Ceni, E., Crabb, D. W., Mello, T., Salzano, R., Grappone, C., Milani, S., Surrenti, E., Surrenti, C., & Casini, A. (2004) · Gut · doi:10.1136/gut.2003.031997 · Cited by 91 · see citing works
Rosiglitazone and Cardiovascular Risk
Bracken, M. B. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071602 · Cited by 42 · see citing works
Rosiglitazone and cardiovascular risk
Kaul, S., & Diamond, G. A. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0062-7 · Cited by 40 · see citing works
Nemenoff, R. A. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318158cf0a · Cited by 32 · see citing works
Metformin and glitazones: do they really help PCOS patients?
Pillai, A., Bang, H., & Green, C. (2007) · PubMed · Cited by 21 · see citing works
Jiang, W. G., Davies, G., Kynaston, H., MASON, M. D., & Fodstad, Ø. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.18.6.1169 · Cited by 13 · see citing works
Rosiglitazone and cardiovascular risk.
Mannucci, E., Monami, M., & Marchionni, N. (2007) · PubMed · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · see citing works
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,065 · see citing works
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · see citing works
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806 · see citing works
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625 · see citing works
Obesity, Diabetes, and Increased Cancer Progression
Kim, D.-S., & Scherer, P. E. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0077 · Cited by 312 · see citing works
Metformin and cancer: new applications for an old drug
Kourelis, T., & Siegel, R. D. (2011) · Medical Oncology · doi:10.1007/s12032-011-9846-7 · Cited by 288 · see citing works
Diabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & SELAGAMSETTY, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 274 · see citing works
Belfiore, A., & Malaguarnera, R. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0074 · Cited by 272 · see citing works
Sulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194 · see citing works
Self-citationChang, C., Lin, J., Wu, L., Lai, M., Chuang, L., & Chan, K. A. (2011) · Hepatology · doi:10.1002/hep.25509 · Cited by 193 · see citing works
Stevens, R., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R., Crowe, F. L., Farmer, A. A., Harrison, S., Hirst, J. A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2653-7 · Cited by 183 · see citing works
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Ferrara, A. M., Lewis, J. D., Quesenberry, C. P., Peng, T., Strom, B. L., Eeden, S. K. V. D., Ehrlich, S. F., & Habel, L. A. (2011) · Diabetes Care · doi:10.2337/dc10-1067 · Cited by 182 · see citing works
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161 · see citing works
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities
Youssef, J., & Badr, M. Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01383.x · Cited by 156 · see citing works
Epidemiological aspects of neoplasms in diabetes
Nicolucci, A. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0187-3 · Cited by 152 · see citing works
Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies
Ferwana, M. S., Firwana, B., Hasan, R., Al-Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H. (2013) · Diabetic Medicine · doi:10.1111/dme.12144 · Cited by 146 · see citing works
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144 · see citing works
Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
Bosetti, C., Rosato, V., Buniato, D., Zambon, A., Vecchia, C. L., & Corrao, G. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0302 · Cited by 144 · see citing works
Habib, S. L., & Rojna, M. (2013) · ISRN Oncology · doi:10.1155/2013/583786 · Cited by 128 · see citing works
Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
Monami, M., Dicembrini, I., & Mannucci, E. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0504-8 · Cited by 115 · see citing works
Self-citationZhao, H.-L., Sui, Y., Qiao, C., Yip, K. Y.-L., Leung, R. K. K., Tsui, S. K., Lee, H.-M., Wong, H. K. T., Zhu, X., Siu, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1164 · Cited by 110 · see citing works
Diabetes and Cancer—An AACE/ACE Consensus Statement
Handelsman, Y., LeRoith, D., Bloomgarden, Z. T., Dagogo-Jack, S. E., EINHORN, D. F., Garber, A. J., Grunberger, G., Harrell, R. M., Gagel, R. F., Lebovitz, H. E., et al. (2013) · Endocrine Practice · doi:10.4158/ep13248.cs · Cited by 99 · see citing works
The Insulin Receptor: A New Target for Cancer Therapy
Malaguarnera, R., & Belfiore, A. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00093 · Cited by 98 · see citing works
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014558289 · Cited by 96 · see citing works
Diabetes and cancer II: role of diabetes medications and influence of shared risk factors
Onitilo, A. A., Engel, J. M., Glurich, I., Stankowski, R. V., Williams, G. M., & Doi, S. A. R. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9971-4 · Cited by 89 · see citing works
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
Vella, V., Nicolosi, M. L., Giuliano, S., Bellomo, M., Belfiore, A., & Malaguarnera, R. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00031 · Cited by 82 · see citing works
Joung, K. H., Jeong, J., & Ku, B. J. (2015) · BioMed Research International · doi:10.1155/2015/920618 · Cited by 83 · see citing works
Carter, J. C., & Church, F. (2009) · PPAR Research · doi:10.1155/2009/345320 · Cited by 75 · see citing works
Chowdhury, T. A. (2010) · QJM · doi:10.1093/qjmed/hcq149 · Cited by 76 · see citing works
Diabetes mellitus, hyperglycaemia and cancer
Simon, D., & Balkau, B. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.04.001 · Cited by 74 · see citing works
Cancer Biology and Prevention in Diabetes
Srivastava, S. P., & Goodwin, J. E. (2020) · Cells · doi:10.3390/cells9061380 · Cited by 75 · see citing works
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 70 · see citing works
Bunt, S. K., Mohr, A. M., Bailey, J. M., Grandgenett, P. M., & Hollingsworth, M. A. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1324-3 · Cited by 65 · see citing works
Malaguarnera, R., Nicolosi, M. L., Sacco, A., Morcavallo, A., Vella, V., Voci, C., Spatuzza, M., Xu, S., Iozzo, R. V., Vigneri, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3177 · Cited by 64 · see citing works
Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
Cheng, W. Y., Huynh, H., Chen, P., Peña‐Llopis, S., & Wan, Y. (2016) · eLife · doi:10.7554/elife.18501 · Cited by 60 · see citing works
Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003640169 · Cited by 59 · see citing works
Diabetes, antihyperglycemic medications and cancer risk
Gallagher, E. J., & LeRoith, D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000433065.16918.83 · Cited by 52 · see citing works
Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations
Sun, G. E. C., & Kashyap, S. R. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/708183 · Cited by 51 · see citing works
Chiu, C.-C., Huang, C., Chen, Y., Chen, T., Liang, Y. J., Lin, S., Chen, J., Leu, H., & Chan, W. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8276 · Cited by 48 · see citing works
Associations between Diabetes Mellitus and Selected Cancers
Pliszka, M., & Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137476 · Cited by 52 · see citing works
Ioannidis, J. P. A., Zhou, Y., Chang, C. Q., Schully, S. D., Khoury, M. J., & Freedman, A. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt372 · Cited by 46 · see citing works
Lin, H. C., Hsu, Y.-T., Kachingwe, B., Hsu, C.-Y., Uang, Y., & Wang, L.-H. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12151 · Cited by 40 · see citing works
Luconi, M., Mangoni, M., Gelmini, S., Poli, G., Nesi, G., Francalanci, M., Pratesi, N., Cantini, G., Lombardi, A., Pepi, M., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0170 · Cited by 41 · see citing works
Tseng, C. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2011.10.003 · Cited by 38 · see citing works
The influence of antidiabetic medications on the development and progression of prostate cancer
Hitron, A., Adams, V. R., Talbert, J., & Steinke, D. T. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.02.005 · Cited by 38 · see citing works
Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group (2013) · Diabetes Care · doi:10.2337/dc11-2197 · Cited by 37 · see citing works
Müssig, K., Staiger, H., Kantartzis, K., Fritsche, A., Kanz, L., & Häring, H. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03132.x · Cited by 37 · see citing works
Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure
Walker, J. J., Johnson, J. A., & Wild, S. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70028-7 · Cited by 37 · see citing works
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13824 · Cited by 36 · see citing works
Shi, S., He, Y., Koya, D., & Kanasaki, K. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12208 · Cited by 33 · see citing works
Shin, C. M., Kim, N., Han, K., Kim, B., Jung, J., Oh, T. J., & Lee, D. H. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.101658 · Cited by 30 · see citing works
The female breast and diabetes
Gouveri, E., Παπάνας, Ν., & Maltezos, E. S. (2011) · The Breast · doi:10.1016/j.breast.2011.02.019 · Cited by 28 · see citing works
Zhou, Z., Jin, R., Gu, Y., Ji, Y., Lou, Y., & Wu, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s524893 · Cited by 27 · see citing works
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 27 · see citing works
Pioglitazone in chemically induced mammary carcinogenesis in rats
Bojková, B., Garajová, M., Kajo, K., Péč, M., Kubatka, P., Kassayová, M., Kisková, T., Orendáš, P., Ahlersová, E., & Ahlers, I. (2010) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e32833ca233 · Cited by 26 · see citing works
Kuntz, S., Mazerbourg, S., Boisbrun, M., Cerella, C., Diederich, M. F., Grillier‐Vuissoz, I., & Flament, S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.021 · Cited by 24 · see citing works
Troglitazone inhibits histone deacetylase activity in breast cancer cells
Davies, G. F., Ross, A. R. S., Arnason, T., Juurlink, B. H. J., & Harkness, T. A. A. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.07.011 · Cited by 23 · see citing works
Muhammed, A., Thomas, C., Kalaiselvan, V., & Undela, K. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2284992 · Cited by 21 · see citing works
Diabetes and cancer relationships (糖尿病与肿瘤的关联性)
Wang, T., Ning, G., & Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21 · see citing works
Adiponectin fine‐tuning of liver regeneration dynamics revealed through cellular network modelling
Correnti, J. M., COOK, D. J., Aksamitiene, E., Swarup, A., Ogunnaike, B. A., Vadigepalli, R., & Hoek, J. B. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.284109 · Cited by 21 · see citing works
Gül, Ö. Ö., Çinkılıç, N., Gul, C. B., Cander, S., Vatan, Ö., Ersoy, C., Yılmaz, D., & Tuncel, E. (2013) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2013.04.024 · Cited by 21 · see citing works
Kong, A. P. S., Yamasaki, A., Ozaki, R., Saito, H., Asami, T., Ohwada, S., Ko, G. T. C., Wong, C. K. H., Leung, G. T. C., Lee, K. F., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01411.x · Cited by 21 · see citing works
Repurposing glucose-lowering drugs for cancer therapy
Luconi, M., Cantini, G., & Crescioli, C. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.010 · Cited by 19 · see citing works
Diabetes: glycaemic control in type 2 (drug treatments).
Gorter, K. J., de Laar, F. A. V., Janssen, P. G. H., Houweling, S. T., & Rutten, G. E. H. M. (2012) · Europe PMC (PubMed Central) · Cited by 19 · see citing works
Diabetes and risk of tumors: oncologic considerations
Rosta, A. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29158 · Cited by 19 · see citing works
The safety of rosiglitazone in the treatment of Type 2 diabetes
Singh, S., & Loke, Y. K. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.5.579 · Cited by 17 · see citing works
Grillier‐Vuissoz, I., & Mazerbourg, S. (2012) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s8-002 · Cited by 17 · see citing works
Protection of pancreatic β-cells against glucotoxicity by short-term treatment with GLP-1
Park, S.-H., Park, J., Shim, H. M., Na, A., Bae, K.-C., Lim, J.-G., & Song, D. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.139 · Cited by 16 · see citing works
Use of thiazolidinedione and cancer risk in Type 2 diabetes: The Hong Kong diabetes registry
Yang, X., So, W., Ronald, C. W., Yu, L. W. L., Kong, A. P. S., Lee, H. M., Xu, G., Ozaki, R., Ko, G. T. C., & Chan, J. C. N. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.03.006 · Cited by 15 · see citing works
Spirulina Reverses Histomorphological Changes in Diabetic Osteoporosis in Pioglitazone Treated Rats
Devesh, C. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s1-006 · Cited by 14 · see citing works
CISD1 Is a Breast Cancer Prognostic Biomarker Associated with Diabetes Mellitus
Liu, F., Dong, Y., Zhong, F., Guo, H., & Dong, P. (2022) · Biomolecules · doi:10.3390/biom13010037 · Cited by 13 · see citing works
Rosiglitazone Shows Partial Oncostatic Effect in Rat Mammary Carcinogenesis
Bojková, B., Kajo, K., Garajová, M., Kubatka, P., PEC, M., Kisková, T., Orendáš, P., Kassayová, M., Korpova, M., & Miklóšová, M. (2012) · Neoplasma · doi:10.4149/neo_2013_007 · Cited by 12 · see citing works
Geoffroy, M., Kleinclauss, A., Grandemange, S., Hupont, S., Boisbrun, M., Flament, S., Grillier‐Vuissoz, I., & Kuntz, S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4378-2 · Cited by 12 · see citing works
Almahmoud, S. A., & Zhong, H. A. (2022) · Biomolecules · doi:10.3390/biom12111614 · Cited by 9 · see citing works
Diabetes and cancer: Could vitamin D provide the link?
Ahmad, S., Chowdhury, T. A., & Boucher, B. J. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.10.005 · Cited by 9 · see citing works
Obesity, Diabetes and Cancer: A Mechanistic Perspective
Cifarelli, V., & Hursting, S. (2015) · International Journal of Diabetology & Vascular Disease Research · doi:10.19070/2328-353x-si04001 · Cited by 9 · see citing works
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 9 · see citing works
Thiazolidinedione derivatives: emerging role in cancer therapy
Latambale, G., & Juvale, K. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11093-3 · Cited by 9 · see citing works
Diabetes, Antihyperglycemic Medications and Cancer Risk: Smoke or Fire?
Gallagher, E. J., & LeRoith, D. (2013) · Endocrine Practice · doi:10.4158/ep13190.ra · Cited by 8 · see citing works
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 6 · see citing works
Metabolic Effects of Pioglitazone in Chemically-Induced Mammary Carcinogenesis in Rats
Bojková, B., Garajová, M., Péč, M., Kubatka, P., Kajo, K., Mokáň, M., Kassayová, M., Orendáš, P., Kisková, T., Ahlersová, E., et al. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9399-2 · Cited by 5 · see citing works
A nationwide, population-based, case-control study
Chen, S., Tsan, Y., Chen, J., Hsieh, H.-I., Lee, C., Lin, H.-H., Wang, J., & Chen, P. (2012) · Cited by 4 · see citing works
Cancer mortality and insulin glargine
Bloomgarden, Z. T., & Handelsman, Y. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00038.x · Cited by 4 · see citing works
Potential Mechanisms Linking Insulin to Cancer
Babichev, Y., Khalid, S., & Fantus, I. G. (2011) · Energy balance and cancer · doi:10.1007/978-1-4419-9911-5_7 · Cited by 4 · see citing works
Wang, T., Zhang, W., Liu, J., Mao, X., Wang, X., Li, J., Huang, Y., Wu, Z., Chen, H., Shi, H., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02561-2 · Cited by 3 · see citing works
McLean, R. C., & Logue, J. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0105-3 · Cited by 3 · see citing works
Influence of metformin therapy on breast cancer incidence and prognosis
Popovic, Ð., POPOVIC, L. S., Stokić, E., Tomić-Naglić, D., Mitrović, M., & Kovačev-Zavišić, B. (2012) · Archive of oncology · doi:10.2298/aoo1204062p · Cited by 2 · see citing works
Yaturu, S. (2013) · InTech eBooks · doi:10.5772/56419
Traitements hypoglycémiants et cancer
Simon, D. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70185-7 · Cited by 1 · see citing works
Zozulińska‐Ziółkiewicz, D., Wysocki, P. J., & Wierusz‐Wysocka, B. (2010) · Onkologia w Praktyce Klinicznej
Durlach, V. (2011) · Médecine thérapeutique · doi:10.1684/met.2011.0332
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.930
Rosiglitazone does not increase the risk of cancer
(2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0940
Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review
Shakour, N., Hosseini, F., Esmaeili, Z., & Hadizadeh, F. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101521
ANTI-INSULIN RESISTANCE TREATMENTS SUPPRESS HER2+ BREAST CANCER GROWTH VIA ALTERING METABOLISM
Chou, P.-C. (2014) · Digital Commons-TMC (Texas Medical Center)
- Authors
- Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- From the Department of Cardiovascular Medicine, Section of Geriatric Cardiology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
- Corresponding author
- Mannucci, Edoardo
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-07-01
- Volume
- 31
- Issue
- 7
- Pages
- 1455-1460
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2453648
- OpenAlex
- W1980115178
- Cited by
- 97
- References
- 22
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 7 · 2014: 7 · 2013: 14 · 2012: 15
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Regione Toscana
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- rosiglitazone, cancer incidence, peroxisome proliferator-activated receptor gamma agonists, drug safety, type 2 diabetes, randomized controlled trials, serious adverse events
- MeSH terms
- Rosiglitazone, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Middle Aged, Neoplasms, Randomized Controlled Trials as Topic, Patient Selection, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
